1. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Issue 10074 (18th March 2017) Authors: Németh, György; Laszlovszky, István; Czobor, Pál; Szalai, Erzsébet; Szatmári, Balázs; Harsányi, Judit; Barabássy, Ágota; Debelle, Marc; Durgam, Suresh; Bitter, István; Marder, Stephen; Fleischhacker, W Wolfgang Journal: Lancet Issue: Volume 389:Issue 10074(2017) Page Start: 1103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies. (November 2017) Authors: Earley, Willie; Durgam, Suresh; Lu, Kaifeng; Laszlovszky, István; Debelle, Marc; Kane, John M. Journal: International clinical psychopharmacology Issue: Volume 32:Number 6(2017:Nov.) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗